Nikhil Wagle, MD
Ophthalmology · Rock Island, ILNPI 1003893454
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $152,824 of the $225,441 with a category attached, or 67.8%. AbbVie accounts for 87.1% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2022 at $55,457 and has fallen 93.2% since, to $3,793 in 2025. Among ophthalmology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 638 payments — averaging $353.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$196K
- Alcon$16K
- Glaukos Corporation$3K
- Rayner Intraocular Lenses Limited$3K
- Aerie Pharmaceuticals, Inc.$2K
- Bausch & Lomb Americas Inc.$946
- plus $4K from 24 others
What the payments were for
- Consulting fees$31,77214%
- Speaking & faculty fees$152,82468%
- Travel & lodging$27,06112%
- Food & beverage$13,7396%
- Gifts$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 342 | $196,304 |
| Alcon | 50 | $16,133 |
| Glaukos Corporation | 24 | $3,173 |
| Rayner Intraocular Lenses Limited | 9 | $2,932 |
| Aerie Pharmaceuticals, Inc. | 13 | $1,504 |
| Bausch & Lomb Americas Inc. | 67 | $946 |
| Rxsight Inc | 9 | $497 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 37 | $483 |
| Biogen | 10 | $475 |
| Sun Pharmaceutical Industries Inc. | 23 | $397 |
| NEW World Medical,inc. | 6 | $364 |
| Genentech USA, Inc. | 3 | $253 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $239 |
| Ocular Therapeutix, Inc. | 7 | $206 |
| Sight Sciences, Inc. | 8 | $195 |
| Tarsus Pharmaceuticals, Inc. | 3 | $154 |
| Novartis | 6 | $149 |
| Coherus Oncology, Inc. | 2 | $149 |
| Apellis Pharmaceuticals, Inc. | 3 | $130 |
| Microsurgical Technology, Inc. | 1 | $118 |
| Harrow Eye, LLC | 1 | $104 |
| Ivantis, Inc | 1 | $99 |
| Genentech, Inc. | 1 | $94 |
| Vantage Technology LLC | 1 | $71 |
| Dompe US, Inc. | 1 | $70 |
| Regeneron Healthcare Solutions, Inc. | 2 | $67 |
| Chiesi USA, Inc. | 1 | $61 |
| Oyster Point Pharma, Inc. | 2 | $43 |
| Omeros Corporation | 1 | $20 |
| Carl Zeiss Meditec USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LUMIGAN$96,194
- VUITY$50,228
- COMBIGAN$22,017
- DURYSTA$17,680
- Rhopressa$16,012
- Rocklatan$14,709
- SIMBRINZA$12,298
- RESTASIS$9,016
- OMIDRIA$2,790
- ALPHAGAN P$2,100
- XEN$500
- VABYSMO$228
- Kahook Dual Blade$173
- Clearpath$173
- Ahmed Glaucoma Valve$173
- Streamline$173
- Via360$173
- Cimerli$134
- Tecnis IOL$131
- iStent$126
How this compares
$225,441 in reported general payments places this provider in the 95th percentile of 773 ophthalmology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 888 | $367,207 |
| CombiganBrimonidine Tartrate/Timolol | 220 | $70,420 |
| RhopressaNetarsudil Mesylate | 116 | $62,809 |
| ProlensaBromfenac Sodium | 159 | $55,033 |
| RestasisCyclosporine | 52 | $51,249 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 242 | $37,086 |
| Alphagan PBrimonidine Tartrate | 114 | $35,317 |
| RocklatanNetarsudil Mesylat/Latanoprost | 56 | $22,216 |
| Prednisolone Acetate | 482 | $20,882 |
| Latanoprost | 2,089 | $19,594 |
| Travoprost | 123 | $16,960 |
| Brinzolamide | 76 | $16,256 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 48 | $13,044 |
| Cyclosporine | 39 | $12,124 |
| MoxifloxacinMoxifloxacin Hcl | 590 | $11,784 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Restasis, Alphagan P | $196,304 | $524,1921,274 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $1,504 | $85,025172 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate | $483 | $60,459181 claims |
| AlconSimbrinza | $16,133 | $13,04448 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $946 | $6,69821 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 773 ophthalmology providers in Illinois.
Other ophthalmology in Rock Island
- Seenu HariprasadChicago$2.3M
- Lisa NijmSpringfield$1.7M
- Kathleen MornoNorth Riverside$1.2M
- Veeral ShethOak Forest$716K
- James KatzDes Plaines$642K
- Mitchell JacksonLake Villa$584K
- David LubeckHomewood$575K
- Parag MajmudarHighland Park$451K
- Daniel OwensLombard$343K
- Yannek LeidermanChicago$312K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.